Anavex Life Sciences Corp., of New York, reported data from a preclinical study of ANAVEX2-73 showing the drug accelerates the maturation of oligodendrocyte precursor cells (OPCs) to oligodendrocytes (OLs), potentially leading to remyelination in MS patients.

Phaserx Inc., of Seattle, received a delisting notice from Nasdaq informing the company that its stock will be suspended from Nasdaq trading on Nov. 1 after Nasdaq rejected its plan to regain compliance with the minimum stockholders' equity requirement.

Orexo AB, of Uppsala, Sweden, said the company will issue a notice of conditional early total redemption of its outstanding SEK342 million (US$40.7 million) (excluding the amount held by the company) senior unsecured callable floating rate bonds due 2018.

Kidney-produced erythropoietin (EPO) desensitizes tumors to the effects of antiangiogenic drugs, improving the understanding of the mechanisms underlying resistance to these agents and potentially, how to improve their therapeutic efficacy.

HONG KONG – Neuraly Inc., a startup from Johns Hopkins School of Medicine and South Korea-based 1st Biotherapeutics Inc. agreed to co-develop brain penetrant c-Abl inhibitors for Parkinson's disease with aims to file an investigational new drug (IND) application with the FDA next year.

ADELAIDE, Australia – Australia's life sciences sector is expected to bring in almost A$3 trillion (US$2.2 trillion) by 2025. The government is pumping funds into the sector and working with industry to update regulations and building needed translational infrastructure to attract global attention.

Gilead Sciences Inc. beat earnings estimates for the third quarter, but analysts seeking to tease out stabilizing trends in the company's declining hepatitis C virus (HCV) franchise were largely disappointed, while overarching concerns about the paucity of promising late-stage programs also helped drive the stock down slightly Friday. Shares of Gilead (NASDAQ:GILD) closed at $77.07, down 81 cents.